CIK 0001829802 · <br>Emerging growth company
Faeth Therapeutics, Inc.
Sign in to watch- Ticker
- FTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 512-200-2982
- Business address
- 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
- Former names
- Sensei Biotherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-20 | van der Horst Edward CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-12-20 | Craver Josiah Principal Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-12-20 | Celebi John PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +355,000 | 355,000 | ||
| 2024-06-11 | Cambrian BioPharma Inc 10% owner | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-06-11 | Peyer James Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-06-11 | Holmen Bob Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-06-11 | English Jessie Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-06-11 | Humer Kristian Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-06-11 | RINGO WILLIAM R Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-06-11 | RICKS THOMAS G Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-06-11 | Vojta Deneen Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2024-02-15 | van der Horst Edward CHIEF SCIENTIFIC OFFICER | Shares withheld for taxes | −2,843 | $0.79 | $2K | 56,070 |
| 2024-02-15 | van der Horst Edward CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2024-02-15 | van der Horst Edward CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +90,102 | 90,102 | ||
| 2024-02-15 | Celebi John PRESIDENT AND CEO | Shares withheld for taxes | −5,891 | $0.79 | $5K | 105,420 |
| 2024-02-15 | Celebi John PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +315,000 | 315,000 | ||
| 2024-02-15 | Celebi John PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +165,889 | 165,889 | ||
| 2024-02-15 | Colgan Erin CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −3,627 | $0.79 | $3K | 67,462 |
| 2024-02-15 | Colgan Erin CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2024-02-15 | Colgan Erin CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +94,128 | 94,128 |
Page 8 of 12 · 238 trades